Evaluation of Hepatoprotective Effects of Piperlongumine Derivative PL 1–3-Loaded Albumin Nanoparticles on Lipopolysaccharide/<scp>d</scp>-Galactosamine-Induced Acute Liver Injury in Mice

Li, Pengxiao; Guo, Xiaoyuan; Liu, Ting; Liu, Qing; Yang, Jie; Liu, Guoyun

doi:10.1021/acs.molpharmaceut.2c00215

Cited by 6 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These 1−3 NPs have demonstrated effective hepatoprotective effects in a mouse model of lipopolysaccharide/D-galactosamine-induced acute liver injury. 84 The important characteristics of acute kidney injury are the loss of renal tubular epithelial cells and a severe inflammatory response. Due to the lack of accurate understanding of the mechanism of acute kidney injury, there is currently no effective treatment for acute kidney injury in clinical practice.…”

Section: Albumin Increases the Solubility Of Poorly Soluble Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems

Wu,

Wang,

Chen

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Albumin, being the most abundant serum protein, has the potential to significantly enhance the physicochemical properties of therapeutic payloads, thereby improving their pharmacological effects. Apart from its passive transport via the enhanced permeability and retention effect, albumin can actively accumulate in tumor microenvironments or inflammatory tissues via receptor-mediated processes. This unique property makes albumin a promising scaffold for targeted drug delivery. This review focuses on exploring different delivery strategies that combine albumin with drug payloads to achieve targeted therapy for inflammatory diseases. Also, albumin-derived therapeutic products on the market or undergoing clinical trials in the past decade have been summarized to gain insight into the future development of albumin-based drug delivery systems. Given the involvement of inflammation in numerous diseases, drug delivery systems utilizing albumin demonstrate remarkable advantages, including enhanced properties, improved in vivo behavior and efficacy. Albumin-based drug delivery systems have been demonstrated in clinical trials, while more advanced strategies for improving the capacity of drug delivery systems with the help of albumin remain to be discovered. This could pave the way for biomedical applications in more effective and precise treatments.

show abstract

Section: Albumin Increases the Solubility Of Poorly Soluble Drugsmentioning

confidence: 99%

“…To address this, researchers have prepared bovine serum albumin nanoparticles loaded with PL1–3 (1–3 NPs). These 1–3 NPs have demonstrated effective hepatoprotective effects in a mouse model of lipopolysaccharide/ d -galactosamine-induced acute liver injury …”

Section: Albumin Related Drug Delivery Strategiesmentioning

confidence: 99%

Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems

Wu,

Wang,

Chen

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…However, despite the promising potential of PPL as both an anticancer therapeutic and a chemosensitizing agent, its pharmacokinetics have not been clarified. Additionally, its poor aqueous solubility and bioavailability limit its therapeutic potential [ 13 , 14 ]; however, efforts have been made on this front in relation to drug delivery systems, especially with nanoparticles and nanoemulsions, which have shown promising results [ 14 , 21 , 22 ].…”

Section: Pro-oxidative Drugs In Preclinical Studymentioning

confidence: 99%

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

et al. 2023

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are metabolic byproducts that regulate various cellular processes. However, at high levels, ROS induce oxidative stress, which in turn can trigger cell death. Cancer cells alter the redox homeostasis to facilitate protumorigenic processes; however, this leaves them vulnerable to further increases in ROS levels. This paradox has been exploited as a cancer therapeutic strategy with the use of pro-oxidative drugs. Many chemotherapeutic drugs presently in clinical use, such as cisplatin and doxorubicin, induce ROS as one of their mechanisms of action. Further, various drugs, including phytochemicals and small molecules, that are presently being investigated in preclinical and clinical studies attribute their anticancer activity to ROS induction. Consistently, this review aims to highlight selected pro-oxidative drugs whose anticancer potential has been characterized with specific focus on phytochemicals, mechanisms of ROS induction, and anticancer effects downstream of ROS induction.

show abstract

“…PL 1-3 owned lower cytotoxicity than PL in Raw264.7 cells and had good oral safety in mice. And it exerted anti-oxidative stress, anti-inflammatory and apoptosis activities, via suppressing the overproductions of reactive nitrogen/oxygen species [NO, malondialdehyde (MDA), and myeloperoxidase (MPO)], pro-inflammatory cytokines [tumor necrosis factor-α ( TNF -α) and interleukin-1β ( IL-1 β)] and the apoptosis-associated proteins of Bax and Caspase 3 ( Wang et al, 2021 ; Li et al, 2022 ). However, the anti-aging (especially anti-brain aging) effect of the active derivative PL 1-3 treatment in the D-gal aging model remains unexplored.…”

Section: Introductionmentioning

confidence: 99%

The protective effect of PL 1-3 on D-galactose-induced aging mice

Li,

Ma,

Wang

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The aging population has become an issue that cannot be ignored, and research on aging is receiving increasing attention. PL 1-3 possesses diverse pharmacological properties including anti-oxidative stress, inhibits inflammatory responses and anti-apoptosis. This study showed that PL 1-3 could protect mice, especially the brain, against the aging caused by D-galactose (D-gal). D-gal could cause oxidative stress, inflammation, apoptosis and tissue pathological injury and so on in aging mice. The treatment of PL 1-3 could increase the anti-oxidative stress ability in the serum, liver, kidney and brain of aging mice, via increasing the total antioxidant capacity and the levels of anti-oxidative defense enzymes (superoxide dismutase, glutathione peroxidase, and catalase), and reducing the end product of lipid peroxidation (malondialdehyde). In the brain, in addition to the enhanced anti-oxidative stress via upregulating the level of the nuclear factor erythroid 2-related factor 2 and heme oxygenase 1, PL 1-3 could improve the dysfunction of the cholinergic system via reducing the active of acetylcholinesterase so as to increase the level of acetylcholine, increase the anti-inflammatory and anti-apoptosis activities via downregulating the expressions of pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α) and pro-apoptosis proteins (Bcl-2 associated X protein and Caspase-3) in the D-gal-induced aging mice, to enhance the anti-aging ability via upregulating the expression of sirtuin 1 and downregulating the expressions of p53, p21, and p16. Besides, PL 1-3 could reverse the liver, kidney and spleen damages induced by D-gal in aging mice. These results suggested that PL 1-3 may be developed as an anti-aging drug for the prevention and intervention of age-related diseases.

show abstract

Evaluation of Hepatoprotective Effects of Piperlongumine Derivative PL 1–3-Loaded Albumin Nanoparticles on Lipopolysaccharide/d-Galactosamine-Induced Acute Liver Injury in Mice

Cited by 6 publications

References 44 publications

Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems

Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

The protective effect of PL 1-3 on D-galactose-induced aging mice

Contact Info

Product

Resources

About